Actively Recruiting
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
Led by University of Utah · Updated on 2026-04-09
245
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.
CONDITIONS
Official Title
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 21 years or older
- Diagnosed with any type of ovarian or pelvic mass
- Treatment naive for current ovarian cancer (if cancer has been diagnosed)
- Treating medical providers plan to perform biopsy, surgery, or diagnostic procedure for ovarian or pelvic mass
- Women aged 21 years or older (control group)
You will not qualify if you...
- Any other active malignancy
- Cancer diagnosis within the last 6 months except non-melanoma skin cancer or carcinoma in situ of the cervix
- Cancer treatment within the last 6 months except non-melanoma skin cancer or carcinoma in situ of the cervix
- Currently receiving chemotherapy, radiation, or other ovarian cancer treatments
- Already had complete ovarian mass removal
- Unable to provide blood sample
- Hospitalization or surgery within last 8 weeks (except minor surgery)
- Renal failure (eGFR < 60 mL/min/1.73m² or dialysis)
- Liver failure or severe liver conditions
- Decompensated or end-stage heart failure
- Poorly controlled diabetes (HbA1c > 9.0%)
- Venous thrombosis, heart attack, or stroke within last 8 weeks
- Currently pregnant or pregnant within last 12 weeks
- Blood transfusion within last 8 weeks
- Personal history of ovarian cancer
- History of bilateral salpingo-oophorectomy
- History of oophorectomy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
S
Syrenna Lisonbee
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here